Biopharmaceuticals declared to take 20% of global pharmaceutical sales

Tuesday, May 16, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, May 15, 2017 /PRNewswire/ --Biopharmaceuticals represent one of the most elegant and sophisticated achievements

of modern science. Compared to small molecules which are synthesized chemically, biopharmaceuticals or biologics are manufactured from biological sources and have proved to be efficacious in the treatment of various chronic and other rare diseases for
which there are no available treatments. The production of biopharmaceuticals reliably at an industrial scale, however, involves highly complex manufacturing capabilities. This involves genetically engineered living cells that must be frozen for storage, thawed without causing any damage, and made to grow in the unusual environment of a reaction vessel.

Here are the key findings of the study:

  • The molecules once produced must then be segregated from the living cells that produced them and the media in which they were made, all without damaging their complex, fragile structures.
  • Such production facilities are also notably more expensive and involve longer time lines to build compared to small molecule drugs. These facilities are also significantly costlier to run, involving long process durations, low yields, costly raw materials, and require a team of highly skilled experts to operate them.
  • The efficacy and safety of biopharmaceuticals, coupled with their ability to address previously untreatable conditions, allows healthcare companies to command higher prices and margins for these drugs.
  • Driven by their numerous advantages over conventional drugs, biopharmaceuticals today represent a big opportunity and represent more than 20% of the total global pharmaceutical sales.
  • The current annual growth rate of biopharmaceuticals is also double that of conventional drugs, and growth is expected to remain robust for the foreseeable future.
  • As a result of their rapid growth, many new players are entering this market and most current manufacturers are expanding their manufacturing capacities.
  • With the anticipated launch of a number of biosimilar drugs in the next five years, we expect a significant expansion in the global biopharmaceutical manufacturing capacity.
  • We expect these trends to make biopharmaceutical manufacturing a very lucrative opportunity for investors and manufacturers.

Category Overview

  • The global biopharmaceutical manufacturing has been categorized on the basis of cell culture which includes mammalian cell culture and microbial cell culture.
  • The largest number of biopharmaceutical products are manufactured using mammalian cell culture.
  • The mammalian-cell based products are more compatible with patients as these have been shown to cause minimum adverse reactions.
  • There has been an increase in the mammalian based products over the past several years.
  • Mammalian cell culture holds a dominating share accounting for 56% in the total biopharmaceutical cell culture market.
  • A significant growth has been observed in the microbial based products.
  • A strong growth in the sales of dominant drugs such as Humalog, Lantus, Neupogen, Neulasta, and Betaseron/Betaferon have sustained the growth of biopharmaceutical manufacturing market.

On the basis of class, the market has been segmented as follows:

  • Monoclonal Antibodies,
  • Recombinant Proteins,
  • Interferon,
  • Granulocyte Colony-Stimulating Factor (G-CSF),
  • Erythropoietin,
  • Human Growth Hormones,
  • Recombinant Human Insulin,
  • Purified Proteins
  • Vaccines.

Regional Market Overview

  • North America accounts for the largest biomanufacturing capacity followed by Europe and Asia.
  • Technological advancements and high healthcare spending are some of the major factors that are driving the growth of the North American market.
  • Driven by factors such as emerging markets, increasing trends of contract manufacturing and a large patient pool, Asia will represent the fastest growing market.

Competitive landscape

  • In the recent past, the in-house manufacturing has experienced a shift towards contract manufacturing due to large volume requirements, cost saving measures and lack of expertise in particular segments of biopharmaceuticals.
  • Currently, the contract manufacturing organizations (CMOs) accounts for around one third of the global biopharmaceutical capacities.
  • The report also covers an in-depth analysis of the key companies operating in the global biopharmaceutical manufacturing market such as Pfizer Inc., Roche, Amgen Inc. Novo Nordisk, AbbVie Inc, Sanofi S.A, Eli Lilly, Johnson & Johnson, Merck Co., etc

About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Email: Tel: +44 208 816 85 48 Website:

To view the original version on PR Newswire, visit:

SOURCE ReportBuyer


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store